MDP — Medexus Pharmaceuticals Balance Sheet
0.000.00%
- CA$87.10m
- CA$130.70m
- $113.05m
- 75
- 95
- 72
- 95
Annual balance sheet for Medexus Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 5.23 | 18.7 | 10 | 13.1 | 5.25 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 15 | 18.8 | 14.4 | 22.4 | 24 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 39.7 | 58.6 | 49.1 | 73 | 72.5 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.1 | 0.795 | 1.22 | 0.899 | 0.778 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 123 | 149 | 139 | 161 | 156 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 34.2 | 39.9 | 48.1 | 83.5 | 66.2 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 98.5 | 130 | 121 | 139 | 125 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 24.3 | 18 | 17.8 | 22.4 | 30.3 |
Total Liabilities & Shareholders' Equity | 123 | 149 | 139 | 161 | 156 |
Total Common Shares Outstanding |